Thomas Magliery, PhD – Biochemistry
Dr. Magliery has substantial expertise in protein design, directed evolution and biophysical characterization, as well as enzymological characterization. As an independent investigator, Dr. Magliery has invented a high-throughput screen for protein thermal stability, used bioinformatics to design stable proteins, and continued to improve chemical biology methods for studying weak protein interactions in cells. Dr. Magliery has studied the enzymology and engineered the physical properties of paraoxonase-1 for chemical warfare countermeasures. In 2012, Dr. Magliery began an effort to engineer stable, high-affinity antibody fragments for use in cancer imaging which has demonstrated that several of these are effective in xenograft mice. As a postdoctoral fellow with Lynne Regan, Dr. Magliery developed a cell-based screen for application of combinatorial methods to protein design, applied statistical analysis to the design of protein motifs, and made substantial improvements to a GFP-based method for trapping protein interactions in living cells. As a graduate student with Peter Schultz, Dr. Magliery engineered orthogonal enzyme-tRNA pairs by directed evolution, and engineered expanded-codon tRNAs, leading to the first living organisms capable of site-specific insertion of unnatural amino acids. In 8 years at OSU, Dr. Magliery has graduated 7 Ph.D. students, 2 M.S. students, and 10 senior honors students. His lab currently hosts 9 graduate students and 3 postdocs, as well as 6 undergraduate researchers and 2 research assistants/technicians.
Charles L. Hitchcock, MD, PhD, FACP – Pathology
Dr. Hitchcock is an Associate Professor-Clinical of Pathology at The Ohio State University (OSU). He has more than 25 years experience with the application of imaging and cytometric technologies to assessing cancer biology. Dr. Hitchcock’s research has centered on improving patient survival by combining imaging with pathology to detect cancer. Since returning to OSU in 1993, he has worked with Dr. Edward W. Martin, Jr. and the other members of Enlyton team providing pathology expertise to various oncology projects.
Dr Hitchcock holds a degree in Medicine and completed his Ph.D. in Anatomy, both at OSU (Columbus, OH). His specialty training includes a Residency in Anatomical and Clinical Pathology at Shands Teaching Hospital, University of Florida (Gainesville, FL) and a Surgical Pathology Fellowship at the University of South Florida (Tampa, FL).
Dr Hitchcock provides Enlyton with expertise in pathology.
Stephen P. Povoski, MD, FACS – Surgical Oncology
Dr. Povoski is an Associate Professor of Surgery at The Ohio State University (OSU) and an Attending Surgical Oncologist at the Arthur G. James Cancer Hospital. His clinical practice focuses upon breast cancer, including special interests in sentinel lymph node mapping and biopsy technology, image-guided minimally invasive breast biopsy technology, and the development and refinement of breast cancer imaging, detection, and therapy technologies. Dr. Povoski has specific clinical research interests in developing innovative strategies for perioperative and intraoperative tumor imaging and detection and in developing tumor-directed surgical and non-surgical therapies, as they relate to many different solid malignancies.
Dr. Povoski holds a Bachelors degree in Biological Sciences (summa cum laude) from the State University of New York (SUNY) at Buffalo (Buffalo, NY). Dr. Povoski holds a degree in Medicine (summa cum laude) from the SUNY Health Science Center at Syracuse (Syracuse, NY). Dr. Povoski completed his general surgery training at the University of Cincinnati Medical Center (Cincinnati, OH). Dr. Povoski completed fellowship speciality training in a Surgical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center (New York, NY).
Dr. Povoski provides expertise in the surgical aspects of cancer imaging, detection, and therapy.
Vish V. Subramaniam, PhD – Applied Physics
Dr. Subramaniam is a Professor, Department of Mechanical Engineering and Chemical Physics Program, The Ohio State University (OSU). Dr. Subramaniam is interested in electromagnetic methods for intraoperative detection and localized imaging of cancer.
Dr. Subramaniam earned his Ph.D. degree from Carnegie Mellon University (Pittsburgh, PA).
Dr. Subramaniam coordinates development of markers for imaging and detection, and serves as scientific advisor on cancer detection techniques and measurement systems.
Duxin Sun, PhD – Pharmacokinetics
Dr. Sun is an Associate Professor of Pharmaceutics, College of Pharmacy, University of Michigan (Ann Arbor, MI). Dr. Sun has considerable experience in tumor targeting, cancer drug discovery and development, and pharmacokinetics.
Dr. Sun earned his Ph.D. degree in Pharmaceutic from the University of Michigan (Ann Arbor, MI).
Dr. Sun oversees use of the proposed PET Tracer in animal model experiments, and the conduct of associated immunogenicity and pharmacokinetics assays.
Ron X. Xu, PhD – Biomedical Engineering
Dr. Xu is an Assistant Professor of Biomedical Engineering at The Ohio State University (OSU). Before joining OSU, Dr. Xu had previously been Director of Technology Development in a medical device company for five years and led the company efforts in technology development, benchtop testing, animal validation studies, and filing FDA 510k applications. His teaching and research interests include medical device design and innovation, multimodal intraoperative cancer detection, minimally invasive cancer imaging, and multifunctional theranostics. Dr. Xu has led the development and validation of multiple handheld devices for cancer detection and intraoperative imaging. Dr. Xu is an inventor/co-inventor of seven published patents and over a dozen provisional patents in the field of cancer imaging.
He earned his Ph.D. degree in Mechanical Engineering from Massachusetts Institute of Technology (Cambridge, MA), and this was followed by postdoctoral training at Stanford University (Palo Alto, CA).
Dr. Xu provides expertise in developing novel multifunctional agents for cancer targeting, multimodal imaging, and synergistic therapy.